ArticleBMC musculoskeletal disorders2026
Clinical characteristics and treatment patterns in ankylosing spondylitis patients undergoing total hip arthroplasty: a single-center retrospective cohort study with a two-decade comparative analysis (2001-2023).
Article in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDespite advances in medical treatment for ankylosing spondylitis (AS), total hip arthroplasty (THA) remains essential for managing advanced hip involvement. However, how the clinical characteristics and real-world treatment patterns of AS patients undergoing THA have evolved over the past two decades, and whether these trends differ according to age at disease onset, remains unclear.
methodsWe conducted a retrospective cohort study of AS patients who underwent THA between 2001 and 2023. Patients were stratified by age at symptom onset (juvenile-onset AS [JAS]: ≤16 years; adult-onset AS [AAS]: >16 years) and surgery period (2001-2011 and 2012-2023). Demographics, clinical characteristics, laboratory parameters, and treatment patterns were compared between groups.
resultsAmong 1,032 patients included, 204 (19.8%) were classified as JAS and 828 (80.2%) as AAS. Comparing 2001-2011 with 2012-2023, median age at surgery increased (36.0 vs. 42.0 years, P < 0.001), employment rate improved (69.3% vs. 82.5%, P < 0.001), and biologic agent use increased (0% vs. 10.5%, P < 0.001). JAS patients showed earlier disease onset (13.0 vs. 22.0 years, P < 0.001), shorter diagnostic delays (4.0 vs. 9.0 years, P < 0.001), but higher inflammatory markers (CRP: 20.9 vs. 11.9 mg/L, P < 0.001) compared to AAS patients. An increasing proportion of unilateral procedures was observed in both groups (JAS: 22.1% to 41.5%; AAS: 33.5% to 52.0%).
conclusionThis two-decade analysis described temporal changes in the clinical characteristics and management patterns of patients with ankylosing spondylitis (AS) undergoing total hip arthroplasty (THA), including increased use of biologic therapy. Within this THA-based surgical cohort, juvenile-onset AS (JAS) patients showed distinct clinical features compared with adult-onset AS (AAS) patients, including earlier disease onset and higher inflammatory burden. An increasing proportion of unilateral procedures was observed over time; however, the reasons for this trend cannot be determined from the present retrospective descriptive design and require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.